
Genome‐wide DNA methylation profiling shows molecular heterogeneity of anaplastic pleomorphic xanthoastrocytoma
Author(s) -
Nakamura Taishi,
Fukuoka Kohei,
Nakano Yoshiko,
Yamasaki Kai,
Matsushita Yuko,
Yamashita Satoshi,
Ikeda Junji,
Udaka Naoko,
Tanoshima Reo,
Shiba Norio,
Tateishi Kensuke,
Yamanaka Shoji,
Yamamoto Tetsuya,
Hirato Junko,
Ichimura Koichi
Publication year - 2019
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/cas.13903
Subject(s) - pleomorphic xanthoastrocytoma , pathology , biology , molecular pathology , genome , dna methylation , computational biology , glioma , medicine , cancer research , gene , genetics , astrocytoma , gene expression
In the revised World Health Organization classification 2016, anaplastic pleomorphic xanthoastrocytoma ( PXA ) has been newly defined as a variant of the PXA entity. Furthermore, some anaplastic PXA were reported to have extremely poor prognosis which showed a type of pediatric glioblastoma ( GBM ) molecular profile. Recent integrated molecular classification for primary central nervous system tumors proposed some differences between histological and molecular features. Herein, in a genome‐wide molecular analysis, we show an extreme aggressive anaplastic PXA that resulted in a pediatric GBM molecular profile. A full implementation of the molecular approach is the key to predict prognosis and decide the treatment strategy for anaplastic PXA .